Doron Therapeutics

Thank you Sharon O'Reilly for the great chat with our CEO, Alessandra Pavesio! Catch the highlights here. #Leadership #Biotech

At Doron Therapeutics, we are proud to be a women-led organization driving innovation in osteoarthritis treatment. As part of the 2% of the all-female co-founded companies that successfully raise capital in 2024 (source: Pitchbook), we know firsthand the challenges, and the immense potential, of women in biotech and beyond. This day is a powerful reminder that while progress has been made, there’s still work to do in bridging the gender gap in funding, leadership, and scientific innovation. We celebrate the women breaking barriers, the allies championing equity, and the future leaders shaping a more inclusive industry. ? Here’s to strong women, groundbreaking science, and a future where female-founded companies are no longer the exception, but the norm. - Alessandra Pavesio, Sarah Caley, MK (Mary Kathryn) Kottke ? #InternationalWomensDay #IWD2025 #WomenInBiotech #WomenInLeadership #Innovation #DoronTherapeutics

At Doron Therapeutics, we are proud to be a women-led organization driving innovation in osteoarthritis treatment. As part of the 2% of the all-female co-founded companies that successfully raise capital in 2024 (source: Pitchbook), we know firsthand the challenges, and the immense potential, of women in biotech and beyond. This day is a powerful reminder that while progress has been made, there’s still work to do in bridging the gender gap in funding, leadership, and scientific innovation. We celebrate the women breaking barriers, the allies championing equity, and the future leaders shaping a more inclusive industry. ? Here’s to strong women, groundbreaking science, and a future where female-founded companies are no longer the exception, but the norm. - Alessandra Pavesio, Sarah Caley, MK (Mary Kathryn) Kottke ? #InternationalWomensDay #IWD2025 #WomenInBiotech #WomenInLeadership #Innovation #DoronTherapeutics

Doron Therapeutics is heading to San Diego next week for the American Academy of Orthopedic Surgeons (AAOS) 2025 Annual Meeting! As we advance MOTYS, our innovative injectable biologic for osteoarthritis, we’re eager to connect with clinicians, researchers, and industry leaders who share our commitment to improving joint health and redefining treatment options for patients worldwide. If you are attending AAOS 2025, let’s connect! Reach out to schedule a meeting or visit us to learn more about our latest progress. See you in San Diego! https://lnkd.in/g3EFZkt ? #AAOS2025 #Orthopaedics #Biotech #Osteoarthritis #Innovation #DoronTherapeutics

We’re excited to announce that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MOTYS?, our placental tissue-derived biologic for knee osteoarthritis (OA), along with Fast Track designation! This milestone reflects the strength of our clinical evidence and the potential of MOTYS to transform the lives of millions suffering from OA-related pain and mobility issues. With RMAT, we gain a critical pathway for accelerated development and regulatory review, bringing us closer to delivering an innovative solution for patients in need. A huge thank you to our dedicated team and the FDA for recognizing the promise of MOTYS. We look forward to working closely with the Agency to advance this therapy! #RMAT #FastTrack #RegenerativeMedicine #KneeOA #Biotech #Innovation https://lnkd.in/eCqkj77X

We’re excited to announce that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MOTYS?, our placental tissue-derived biologic for knee osteoarthritis (OA), along with Fast Track designation! This milestone reflects the strength of our clinical evidence and the potential of MOTYS to transform the lives of millions suffering from OA-related pain and mobility issues. With RMAT, we gain a critical pathway for accelerated development and regulatory review, bringing us closer to delivering an innovative solution for patients in need. A huge thank you to our dedicated team and the FDA for recognizing the promise of MOTYS. We look forward to working closely with the Agency to advance this therapy! #RMAT #FastTrack #RegenerativeMedicine #KneeOA #Biotech #Innovation https://lnkd.in/eCqkj77X

Doron Therapeutics is attending #BiotechShowcase, January 13–15, 2025. Register now to meet one-to-one: biotechshowcase.com

We are thrilled to announce the closing of our initial Series A round raising $11M in aggregate funding to take MOTYS a biologic injectable drug for knee osteoarthritis into Phase 3 clinical studies. SPRIM Global Investments led the round.

Alessandra Pavesio, CEO of Doron Therapeutics was a podium presenter of the positive results from our Phase 2 study of MOTYS in Knee Osteoarthritis (OA) at the recent OARSI (World Congress on Osteoarthritis) in Vienna, Austria. After the presentation the Doron team met with a number of prominent opinion leaders in OA and OA clinical trial design who assured us that the data was outstanding and indicative of a clear benefit for knee OA patients. Efficacy and safety of an intra-articular placental tissue particulate (MOTYS/PTP-001) in symptomatic knee osteoarthritis over 26 weeks: A placebo-controlled, double-blind?randomized clinical trial https://lnkd.in/gMdmhJhu